Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK154
- Development stage
- Phase 1
- Lead developer
- Kangfang Sainuo Pharmaceutical
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
AK154 is a personalized neoantigen mRNA cancer vaccine developed by Akeso. It is designed to encode patient-specific tumor neoantigens identified through genomic sequencing of the patient's tumor. The vaccine aims to stimulate the immune system, specifically T cells, to recognize and attack tumor cells expressing these unique antigens. It is currently being investigated in clinical trials for the treatment of surgically resectable pancreatic ductal adenocarcinoma (PDAC), both as a monotherapy and in combination with other immunotherapies like AK104 (cadonilimab, a PD-1/CTLA-4 bispecific antibody) or AK112 (ivonescimab, a PD-1/VEGF bispecific antibody).
- Other names
- Neoantigen personalized mRNA vaccine AK154
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on AK154.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK154.